Exploring New Paths for MS Treatment
Research from the University of Alberta’s Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the treatment of multiple sclerosis (MS). The research, published in the Journal of Neuroinflammation, examines a novel therapeutic strategy to reduce inflammation in the brain – a key contributing factor to the muscle disability associated with MS. According to the researchers, most current MS treatments act on the immune system to reduce inflammation on the brain. The downside is that as medications get stronger, they suppress the immune system to the point where patients must cope with significant side effects. In the study, the UAlberta scientists examined an enzyme called granzyme B in cytotoxic cells as a possible therapeutic target for reducing inflammation without significantly suppressing the immune system response. To read more, click here.
Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland
12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.